International Myeloma Workshop (IMW)

Seven of 10 evaluable patients achieved minimal residual disease negativity after cilta-cel treatment.

Overall response rate was 95%, including 75% of patients who achieved a complete response (CR) or better, with a median follow-up of 5.8 months at data cutoff.

The associate professor from the Harold C. Simmons Comprehensive Cancer Center of UT Southwestern Medical Center discussed the latest data from the KarMMA trial.